132 related articles for article (PubMed ID: 30300165)
1. Markers of mineralocorticoid receptor function: changes over time and relationship to response in patients with major depression.
Murck H; Braunisch MC; Konrad C; Jezova D; Kircher T
Int Clin Psychopharmacol; 2019 Jan; 34(1):18-26. PubMed ID: 30300165
[TBL] [Abstract][Full Text] [Related]
2. Target-based biomarker selection - Mineralocorticoid receptor-related biomarkers and treatment outcome in major depression.
Büttner M; Jezova D; Greene B; Konrad C; Kircher T; Murck H
J Psychiatr Res; 2015; 66-67():24-37. PubMed ID: 25959615
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid receptor-related markers and outcome of major depression: focus on blood pressure and electrolytes.
Murck H; Ploch M; Montgomery S
Int Clin Psychopharmacol; 2018 Jul; 33(4):224-228. PubMed ID: 29489494
[TBL] [Abstract][Full Text] [Related]
4. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
5. Antidepressive treatment with amitriptyline and paroxetine: effects on saliva cortisol concentrations.
Deuschle M; Hamann B; Meichel C; Krumm B; Lederbogen F; Kniest A; Colla M; Heuser I
J Clin Psychopharmacol; 2003 Apr; 23(2):201-5. PubMed ID: 12640223
[TBL] [Abstract][Full Text] [Related]
6. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
[TBL] [Abstract][Full Text] [Related]
7. Routinely accessible parameters of mineralocorticoid receptor function, depression subtypes and response prediction: a post-hoc analysis from the early medication change trial in major depressive disorder.
Engelmann J; Murck H; Wagner S; Zillich L; Streit F; Herzog DP; Braus DF; Tadic A; Lieb K; Műller MB
World J Biol Psychiatry; 2022 Oct; 23(8):631-642. PubMed ID: 34985381
[TBL] [Abstract][Full Text] [Related]
8. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study.
Otte C; Hinkelmann K; Moritz S; Yassouridis A; Jahn H; Wiedemann K; Kellner M
J Psychiatr Res; 2010 Apr; 44(6):339-46. PubMed ID: 19909979
[TBL] [Abstract][Full Text] [Related]
10. Genetic, molecular and clinical determinants for the involvement of aldosterone and its receptors in major depression.
Murck H; Büttner M; Kircher T; Konrad C
Nephron Physiol; 2014; 128(1-2):17-25. PubMed ID: 25376974
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
Lin CH; Lin SH; Jang FL
J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
[TBL] [Abstract][Full Text] [Related]
12. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
[TBL] [Abstract][Full Text] [Related]
13. Electroretinographic assessment in major depressed patients receiving duloxetine: might differences between responders and non-responders indicate a differential biological background?
Fornaro M; Bandini F; Ogliastro C; Cordano C; Martino M; Cestari L; Escelsior A; Rocchi G; Colicchio S; Perugi G
J Affect Disord; 2011 Dec; 135(1-3):154-9. PubMed ID: 21820182
[TBL] [Abstract][Full Text] [Related]
14. Peripheral vascular endothelial growth factor level is associated with antidepressant treatment response: results of a preliminary study.
Halmai Z; Dome P; Dobos J; Gonda X; Szekely A; Sasvari-Szekely M; Faludi G; Lazary J
J Affect Disord; 2013 Jan; 144(3):269-73. PubMed ID: 23021824
[TBL] [Abstract][Full Text] [Related]
15. HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients.
Binder EB; Künzel HE; Nickel T; Kern N; Pfennig A; Majer M; Uhr M; Ising M; Holsboer F
Psychoneuroendocrinology; 2009 Jan; 34(1):99-109. PubMed ID: 18829172
[TBL] [Abstract][Full Text] [Related]
16. Nighttime heart rate predicts response to depression treatment in patients with coronary heart disease.
Carney RM; Freedland KE; Steinmeyer BC; Rubin EH; Stein PK; Rich MW
J Affect Disord; 2016 Aug; 200():165-71. PubMed ID: 27136414
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
[TBL] [Abstract][Full Text] [Related]
18. A history of early life parental loss or separation is associated with successful cognitive-behavioral therapy in major depressive disorder.
Niciu MJ; Abdallah CG; Fenton LR; Fasula MK; Black A; Anderson GM; Sanacora G
J Affect Disord; 2015 Nov; 187():241-4. PubMed ID: 26363143
[TBL] [Abstract][Full Text] [Related]
19. Symptom clusters as predictors of late response to antidepressant treatment.
Trivedi MH; Morris DW; Grannemann BD; Mahadi S
J Clin Psychiatry; 2005 Aug; 66(8):1064-70. PubMed ID: 16086624
[TBL] [Abstract][Full Text] [Related]
20. Curcumin and major depression: a randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change.
Lopresti AL; Maes M; Meddens MJ; Maker GL; Arnoldussen E; Drummond PD
Eur Neuropsychopharmacol; 2015 Jan; 25(1):38-50. PubMed ID: 25523883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
